积分兑换
关注公众号
收藏产品 产品详情
特异性（Specificity）
This product is a specific antibody specifically reacts with Eribulin.
抗体来源（Source）
Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号（Clone）
1M2B11
亚型（Isotype）
Rabbit IgG | Rabbit Kappa
偶联（Conjugate）
Unconjugated
应用（Application）
ApplicationRecommended UsageELISA0.2-125 ng/mL纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
推荐产品
数据展示
活性（Bioactivity）-ELISA
Immobilized Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) at 1 μg/mL, add Farletuzumab Ecteribulin in the 100% Human Serum and then add Biotinylated Human FOLR1, Fc,Avitag (Cat. No. FO1-H82F9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Farletuzumab Ecteribulin at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) with a linear range of 0.06-2 ng/mL (QC tested).
Protocol
Serial dilutions of Eribulin were added into Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b): Farletuzumab ecteribulin binding reactions. The half maximal inhibitory concentration (IC50) is 0.5451 μg/mL (Routinely tested).
Protocol
交叉验证-Cross Verification
ELISA binding of Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) with Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Farletuzumab Ecteribulin, IgG1-MMAF and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Farletuzumab Ecteribulin, IgG1-MMAF and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) is specific to Farletuzumab Ecteribulin, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), IgG1-MMAF and Trastuzumab-DM1 (Routinely tested).
用户评价 发表评论
联系我们 
项目合作 